<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610310</url>
  </required_header>
  <id_info>
    <org_study_id>105HV103</org_study_id>
    <nct_id>NCT01610310</nct_id>
  </id_info>
  <brief_title>Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) Delivered by Pre-filled Syringe (PFS) or Autoinjector in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and
      tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or
      prefilled syringe (PFS) in healthy volunteers to support the development of the autoinjector.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, 2-sequence, 2-period crossover study that will be conducted
      at a single site in the United States to characterize the PK profile, safety and tolerability
      of peginterferon beta-1a delivered by autoinjector or PFS. Participants will be randomized in
      a 1:1 ratio to receive a single dose of peginterferon beta-1a at Day 1 delivered by either
      autoinjector or PFS, followed by a single dose of peginterferon beta 1a delivered by the
      other device at Day 22. The total duration of study participation is up to 3 months for each
      participant. Participants will complete a follow-up visit at Day 50 after the end of
      treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the time-concentration curve for serum concentrations of peginterferon beta-1a from time zero to infinity post dose (AUC0-âˆž)</measure>
    <time_frame>For 11 days (multiple timepoints) after each dose on Day 1 and 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of peginterferon beta-1a</measure>
    <time_frame>For 11 days (multiple timepoints) after each dose on Day 1 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory assessments</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign changes</measure>
    <time_frame>Day 1 up to Day 50)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical exam changes</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram changes</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician injection site assessment</measure>
    <time_frame>Days 1+2, 22+23</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>peginterferon beta-1a PFS/autoinjector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon beta-1a autoinjector / PFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)</intervention_name>
    <description>125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22</description>
    <arm_group_label>peginterferon beta-1a autoinjector / PFS</arm_group_label>
    <arm_group_label>peginterferon beta-1a PFS/autoinjector</arm_group_label>
    <other_name>BIIB017</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIIB017 (peginterferon beta-1a) Autoinjector</intervention_name>
    <description>125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22</description>
    <arm_group_label>peginterferon beta-1a autoinjector / PFS</arm_group_label>
    <arm_group_label>peginterferon beta-1a PFS/autoinjector</arm_group_label>
    <other_name>BIIB017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        1. Must have a body mass index (BMI) of 19 to 29 kg/m^2, inclusive, and a minimum body
        weight of 50.0 kg

        Key Exclusion Criteria:

          1. History of any clinically significant laboratory abnormalities, malignancies, cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, or other major diseases

          2. Female subjects who are pregnant or breastfeeding

          3. Any previous treatment with prescription or investigational pegylated drugs.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SC</keyword>
  <keyword>PEG</keyword>
  <keyword>Inteferon</keyword>
  <keyword>PK</keyword>
  <keyword>Subcutaneous</keyword>
  <keyword>PEGylated</keyword>
  <keyword>Autoinjector</keyword>
  <keyword>Injectable</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

